• 1. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 4. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl aryl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Alkyl aryl ethers

6-Bromo-4-Methoxypyridin-3-ol (CAS No. 1211536-66-1): A Comprehensive Overview

6-Bromo-4-methoxypyridin-3-ol (CAS No. 1211536-66-1) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique 6-bromo and 4-methoxy substituents on a pyridine ring, exhibits a range of biological activities that make it a valuable candidate for various applications, including drug discovery and development.

The chemical structure of 6-bromo-4-methoxypyridin-3-ol is defined by its molecular formula C₇H₇BrNO₂. The presence of the bromine atom at the 6-position and the methoxy group at the 4-position imparts specific electronic and steric properties to the molecule, which are crucial for its biological activity. These substituents influence the compound's reactivity, solubility, and binding affinity to various biological targets.

In recent years, extensive research has been conducted to explore the potential therapeutic applications of 6-bromo-4-methoxypyridin-3-ol. One of the key areas of interest is its role as a potential lead compound for the development of novel anti-inflammatory agents. Studies have shown that this compound can effectively inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in vitro and in vivo models. This property makes it a promising candidate for treating inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Beyond its anti-inflammatory properties, 6-bromo-4-methoxypyridin-3-ol has also been investigated for its potential as an anticancer agent. Research has demonstrated that this compound can induce apoptosis in various cancer cell lines, including breast cancer, lung cancer, and colon cancer cells. The mechanism of action appears to involve the modulation of key signaling pathways, such as the PI3K/AKT and MAPK pathways, which are frequently dysregulated in cancer cells.

The pharmacokinetic properties of 6-bromo-4-methoxypyridin-3-ol have also been studied to assess its suitability as a drug candidate. Preliminary data indicate that this compound exhibits favorable oral bioavailability and a reasonable half-life in animal models. These characteristics suggest that it could be developed into an orally available therapeutic agent with sustained efficacy.

In addition to its direct biological activities, 6-bromo-4-methoxypyridin-3-ol has been used as a building block in the synthesis of more complex molecules with enhanced therapeutic potential. For example, researchers have synthesized derivatives of this compound by introducing additional functional groups or modifying the existing substituents. These derivatives have shown improved potency and selectivity for specific targets, further expanding the scope of applications for this core structure.

The safety profile of 6-bromo-4-methoxypyridin-3-ol is another critical aspect that has been evaluated in preclinical studies. Toxicity assessments in animal models have indicated that this compound is generally well-tolerated at therapeutic doses. However, further investigations are needed to fully understand its long-term safety and potential side effects in humans.

In conclusion, 6-bromo-4-methoxypyridin-3-ol (CAS No. 1211536-66-1) represents a promising compound with diverse biological activities and therapeutic potential. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further development in various areas of medicinal chemistry and pharmaceutical research. Ongoing studies are expected to uncover new applications and optimize its use in clinical settings.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)